Perspective Map
Drug Policy: What Both Sides Are Protecting
A father lost his daughter at 23 to a fentanyl overdose. She had started with prescription pills, moved to heroin when the pills got expensive, and died in a gas station bathroom. The detail that stays with him: she was afraid to call for help. Afraid of arrest. Afraid of what her family would think. He supports harm reduction now — not because he approves of drug use, but because he knows she might be alive if she hadn't been afraid of the call.
A mother on the north side of the same city has watched the corner in front of her building serve as a drug market for fifteen years. She has watched the boys it recruits get younger. She has watched her son navigate that corner every day on the way to school. She wants it gone. She wants enforcement — not because she is indifferent to addiction, but because she has seen what the corner does, and she is asking to be protected from it.
Neither of them is wrong about what they have seen. The drug policy debate has become a contest between their testimonies. The sensemaking question is: what would it take to take both seriously at once?
What criminalization is protecting
People who support strict enforcement of drug laws are not simply indifferent to the suffering of people with addiction. At the core of the criminalization position are several claims that deserve honest engagement.
They are protecting social norms against self-destructive behavior. The argument is not only consequentialist — that punishment deters drug use — but expressive: law makes a statement about what a community values. Decriminalization, on this view, is not merely a policy change; it is a moral signal. Communities with strong religious or traditional frameworks often feel that treating addiction as a medical condition rather than a moral failure removes an important source of accountability, both social and personal.
They are protecting community order in the places that bear the most direct cost. The mother watching the corner is not expressing abstract principle. Open drug markets generate real disorder: property crime, violence between competing suppliers, intimidation of residents, an environment that makes it harder to raise children or run a business. The people most exposed to this disorder are often not wealthy enough to move away from it. Their request for enforcement is a request to be taken seriously.
They are protecting children from normalization. One of the most consistent concerns in criminalization arguments is that decriminalization sends the message that drug use is acceptable, and that this message is absorbed most readily by young people whose risk-assessment capacities are still developing. This concern predates the opioid crisis and has not been resolved by it.
They are protecting families who have lost people. For many who have watched someone destroy their life through addiction, the harm reduction framework — which treats addiction as a chronic condition requiring management rather than abstinence — can feel like abandonment. The demand for a higher standard, including the demand for consequences, is sometimes an expression of grief, not cruelty.
What harm reduction is protecting
People who support decriminalization, safe supply, or supervised consumption sites are not indifferent to community order or the costs of addiction. They are making a specific empirical claim: the current approach is killing people it doesn't have to kill.
They are protecting lives by changing what people die of. In 2001, Portugal decriminalized the personal possession of all drugs — not legalization, but decriminalization, paired with expansion of treatment and social support. By the mid-2010s, HIV infections among people who inject drugs had dropped from roughly fifty-two percent of new cases to less than seven percent. Drug-induced mortality fell to among the lowest in the European Union. Glenn Greenwald's 2009 report for the Cato Institute documented these results and assessed the policy as a success — notable because the Cato Institute's politics do not lean toward public health interventions.
They are protecting the unconditional worth of people with substance use disorders. Nora Volkow, director of the National Institute on Drug Abuse, has written extensively — including in the New England Journal of Medicine with Thomas McLellan — that addiction is a chronic brain disorder, not a moral failing but a condition that alters cognition, impulse control, and decision-making in ways that make "just stop" an inadequate response. If addiction is a disease, then treating sick people as criminals requires a justification that goes beyond disapproval of their choices. The harm reduction position is that their worth is not conditional on having made better ones.
They are protecting public health in the literal sense of communicable disease. Criminalized drug use drives needle sharing. Needle sharing drives HIV, hepatitis C, and bacterial infections. Harm reduction programs — needle exchanges, supervised injection sites, naloxone distribution — have documented records of reducing transmission and saving lives, often at relatively low cost. The people who contract these diseases extend the health consequences of the policy well beyond those who use drugs.
They are protecting the people the drug war has been most costly for. Johann Hari's history of drug prohibition, Chasing the Scream (2015), documents how Harry Anslinger's Federal Bureau of Narcotics explicitly targeted marijuana in ways designed to criminalize Mexican immigrants and Black jazz musicians. The asymmetry in enforcement — who gets arrested for possession, who faces felony charges, who serves time — has fallen overwhelmingly on Black and Brown communities. Michelle Alexander's The New Jim Crow (2010) documented this pattern in careful detail. The harm reduction argument includes: whose safety has been protected, and whose has not, is itself part of the policy.
Where the real disagreement lives
Both sides want less addiction and safer communities. The dispute is three layers deeper than it usually appears.
Conditional or unconditional worth? This is the core fault line. The criminalization framework often operates on an implicit premise: that people whose choices led to addiction have incurred a debt — to their families, to the communities that bear the disorder — and that consequences are part of how that debt is reckoned. Harm reduction operates on a different premise: that no one forfeits a fundamental claim to care because of a substance use disorder, regardless of how they arrived at it. These are genuinely different moral frameworks, and neither is obviously wrong. They produce different policies even when the empirical evidence is identical.
Compared to what? Advocates for stricter enforcement often compare decriminalization to a world with less drug use — one where the signal sent by law reduces the number of people who start. Harm reduction advocates compare the current policy to a world in which fewer people die and fewer are imprisoned. These are different baseline assumptions, which is why empirical evidence about outcomes is surprisingly difficult to share across the debate: the two sides are asking different questions of the data.
Whose costs are being centered? Drug-related crime, open markets, and public disorder are visible in communities in ways that deaths in private spaces are not. Mass incarceration operates out of sight. HIV transmission shows up as statistics. The costs that are most visible tend to drive political response; costs that are diffuse and fall on already-marginalized people are harder to mobilize around. The drug policy debate reflects a long-running disagreement about whose pain demands the most urgent response.
What sensemaking surfaces
The drug policy debate, like the immigration debate, is several debates conducted as one. Marijuana is not opioids. Opioids are not methamphetamine. Personal use is not trafficking. Addiction treatment policy is not the same question as drug criminalization policy. Treating all of these as a single question — are you "for" or "against" drugs? — produces policy that manages none of them well.
The "moral message" function of criminalization is real. There is a legitimate argument that the signal sent by law shapes behavior, especially among young people, and that this matters independent of enforcement effects. But that argument comes at a specific, countable cost: people who are sick dying in circumstances they wouldn't choose, because the cost of seeking help is too high. Acknowledging the moral message function doesn't require pretending the cost doesn't exist. It requires asking whether the message could be sent at lower human cost.
The racial architecture of the drug war is not accidental. Neuroscientist Carl Hart, writing in Drug Use for Grown-Ups (2021) about his own drug use and his research, argues that drug prohibition has functioned primarily as social control of populations deemed threatening, not as public health policy. Whatever one thinks of that argument in full, the enforcement record is clear: the war on drugs has fallen hardest on communities that were not in a position to resist it. Any drug policy that omits this history is incomplete.
The strongest version of each position would acknowledge what its approach costs. A criminalization advocate who takes community order seriously should also take seriously that the communities asking for enforcement are often the same communities most harmed by aggressive policing — the demand is not for more arrests, but for safer streets, and these are not always the same thing. A harm reduction advocate who takes unconditional worth seriously should also take seriously the mother on the corner, who is also asking to be protected — not from an abstract policy failure, but from the reality outside her building every day.
What is underneath all of it: a question about what we owe each other. Not just what we owe the person with the addiction, but what we owe the community bearing the disorder, the family watching someone disappear, the child walking past the corner to school. Drug policy forces the question in its sharpest form: when someone has made choices we wish they hadn't, and those choices have real costs for others, what is owed — and to whom?
Patterns at work in this piece
Three of the four recurring patterns appear here — with one at the very heart of the debate. See What sensemaking has taught Ripple so far for the full framework.
- Conditional vs. unconditional worth. This is the sharpest instance of this pattern across all the perspective maps on this site. The question underneath drug policy is not really about policy: it is whether a person who made risky choices — and whose choices have caused harm — is still owed unconditional care. The mother in the opening scene applies a logic of conditional worth that most people hold in some form. The father has learned, through grief, that conditional worth has a body count.
- Whose costs are centered. The enforcement side centers community disorder — the compromised safety of people who didn't choose addiction and can't opt out of its consequences. The harm reduction side centers overdose deaths, HIV transmission rates, and the mass incarceration of people whose primary offense is substance use. Which costs you count determines which intervention looks obvious.
- Compared to what. Prohibition advocates compare harm reduction to a world without widespread drug use — not the actual alternative. Harm reduction advocates compare their approach to prohibition — which has been tried and produced the costs being cited. The Portugal evidence (Greenwald, 2009) helps make this comparison concrete: what actually happened when decriminalization was tried.
Structural tensions worth naming
- The federalism trap: In the United States, state-level marijuana legalization operates against a federal backdrop in which cannabis remains a Schedule I controlled substance under the Controlled Substances Act — the same schedule as heroin, carrying no accepted medical use designation. This creates a structural tension that has no clean resolution: state-legal cannabis businesses cannot open accounts at federally insured banks, cannot take standard business deductions under the federal tax code (Section 280E), cannot transport products across state lines, and operate with the constant legal vulnerability of a federal enforcement choice. The policy debate treats "legalization" as a discrete outcome, but the federalism gap means that state legalization without federal rescheduling is a permanently unstable equilibrium — not because of policy disagreement, but because of the constitutional structure of dual sovereignty. The same tension applies to harm reduction services: needle exchanges and supervised consumption sites operate in gray zones where state permission coexists with federal paraphernalia law.
- The international treaty constraint: The 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs create binding obligations on signatory states to maintain domestic criminalization of controlled substances. These treaties were negotiated during the Cold War under American leadership and reflect a prohibitionist consensus that has since fractured — but the treaty architecture constrains what domestic policy changes are possible without formal treaty renegotiation or withdrawal. Uruguay and Canada legalized cannabis in acknowledged technical violation of the 1961 Convention; the INCB (International Narcotics Control Board) formally criticized both countries without triggering enforcement. The structural tension is that the international framework treats drug policy as a global public good problem (trafficking respects no borders), while the domestic debate treats it as a matter of national sovereignty. States that want to pursue harm reduction or decriminalization as full policy face a governance architecture not designed to accommodate that choice.
- The pharmaceutical asymmetry: The opioid crisis was produced by substances that were legally manufactured, marketed, and prescribed within the regulatory framework designed to ensure drug safety. OxyContin, Vicodin, and similar products went through FDA approval, carried DEA Schedule II classification, and were distributed through licensed pharmacies and physicians. The regulatory apparatus that was supposed to prevent harm enabled it at scale. The drug policy debate routinely frames the choice as "criminal enforcement of illicit drugs" versus "harm reduction for illicit drug users," but the largest drug-related public health disaster of the early 21st century operated through legal channels. This asymmetry — stricter enforcement for illicit substances, regulatory failure for licensed pharmaceuticals — is a structural feature of how drug policy actually operates, not an accident, and it complicates every argument that frames enforcement as protection and harm reduction as permissiveness.
Further reading
- Johann Hari, Chasing the Scream: The First and Last Days of the War on Drugs (Bloomsbury, 2015) — a thoroughly reported narrative history of drug prohibition, from Harry Anslinger's racially targeted enforcement in the 1930s through the contemporary fentanyl crisis. Strongest on the human cost and the origins of criminalization; essential entry point for readers new to the policy history.
- Glenn Greenwald, Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies (Cato Institute, 2009) — the most widely cited account of the Portuguese decriminalization experiment; written for a libertarian think tank, which makes it a useful demonstration that the case for decriminalization is not confined to the political left.
- Nora Volkow and Thomas McLellan, "Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies," New England Journal of Medicine, vol. 374 (2016) — on the neuroscience of addiction and the medical consensus that it is a chronic brain disorder rather than a moral failing; directly relevant to the conditional worth question at the center of this debate.
- Michelle Alexander, The New Jim Crow: Mass Incarceration in the Age of Colorblindness (The New Press, 2010) — the most influential account of how the drug war has functioned as a mechanism of racial control; essential context for understanding whose costs have been centered and whose have not in a century of American drug enforcement.
- Carl Hart, Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear (Penguin Press, 2021) — a neuroscientist's argument for drug legalization from a liberty rather than public health frame, drawing on his own recreational use and his research on addiction; disrupts the assumption that drug reform is primarily a health argument, and raises the question of who gets to decide what risks adults may take with their own bodies.
- James Q. Wilson, "Against the Legalization of Drugs," Commentary (February 1990) — the most carefully argued statement of the criminalization case, written by the political scientist best known for broken-windows theory. Wilson does not dismiss harm reduction; he argues that some drugs are so destructive to personality and agency — cocaine is his primary example — that the moral message function of law justifies prohibition even at the cost of enforcement harms. An essential counterpoint to Hart and Greenwald; anyone who wants to understand why serious people favor prohibition needs to grapple with this piece.
- Beth Macy, Dopesick: Dealers, Doctors, and the Drug Company that Addicted America (Little, Brown, 2018) — reported narrative tracing the opioid epidemic from its pharmaceutical origins (Purdue Pharma's aggressive marketing of OxyContin in Appalachian and rural communities) through the fentanyl crisis. The opening vignette in this map — a daughter moving from prescription pills to heroin to a fentanyl overdose — is not an edge case; Macy documents it as a pattern. The book complicates the enforcement/reform binary by showing that the initial supply was legal and corporate, not street-level.
- Mark Kleiman, Jonathan Caulkins, and Angela Hawken, Drugs and Drug Policy: What Everyone Needs to Know (Oxford University Press, 2011) — the most useful evidence-based overview of the policy landscape, written by scholars who decline the advocacy framing. Covers deterrence research, treatment efficacy, the economics of drug markets, and the actual effects of various enforcement strategies. Particularly valuable for the "compared to what" problem at the center of this debate: it helps readers identify which empirical questions are actually settled and which remain genuinely open.
See also
- How do we repair harm? — the framing essay for the repair question underneath drug policy: when prohibition, addiction, overdose, and neighborhood disorder have all produced harm, the live dispute is whether repair should move through punishment, treatment, decriminalization, restitution, or a public-health system that refuses the old moral sorting.
- What is a life worth? — the framing essay for the dignity question this map keeps returning to: whether people who use drugs retain an unconditional claim on care, safety, and public concern, or whether that claim is made conditional on sobriety, compliance, productivity, or innocence.
- Criminal Justice: What Both Sides Are Protecting — drug offenses have driven a large share of mass incarceration; the debate about what prisons are for, and what sentences should accomplish, maps directly onto what we think drug enforcement should be doing. Retributive, rehabilitative, and restorative frameworks each produce a different drug policy.
- Criminal Sentencing Reform: What Each Position Is Protecting — drug offenses are among the central cases in the sentencing debate; mandatory minimums were deployed most aggressively in the drug context, and the argument about whether sentences should be punitive, rehabilitative, or restorative plays out in drug sentencing more visibly than almost anywhere else. What you think drug enforcement should accomplish determines which sentencing framework you reach for when a person convicted of a drug offense stands before a judge.
- Police Reform: What Each Position Is Protecting — drug enforcement is among the most common grounds for police encounters; the question of how police interact with people in public is inseparable from what they are expected to do about open drug markets, overdoses, and possession. Several cities that have expanded harm reduction have also expanded alternatives to police-first response.
- Community and Belonging: What Both Sides Are Protecting — the mother at the corner and the father who lost his daughter are both asking about the same community: who gets protected, and from what. The map on community belonging explores how neighborhood fabric forms and frays, and what conditions make it possible to raise children in safety.
- Mental Illness: What Both Frameworks Are Protecting — substance use disorder and mental illness overlap significantly both in population and in how society responds; the medical model vs. accountability model tension in this map has a direct parallel in the debate about whether mental illness is a medical condition requiring treatment or a character failure requiring consequences.
- Drug Legalization and Harm Reduction: What Each Position Is Protecting — the next layer of this debate: once the case for decriminalization is accepted, what should a post-prohibition system look like? Commercial legalization, public health supply, sobriety-first treatment, and international treaty reform each produce different answers to the question this map opens.
- Addiction and the Criminal Legal System: What Each Position Is Protecting — the layer beneath both prior drug maps: what happens to people whose drug use brings them into criminal legal contact regardless of formal policy? Drug courts, therapeutic jurisprudence, harm reduction in carceral settings, and the structural critique of therapeutic net-widening each engage this question directly.
- Drug Sentencing Reform and Racial Disparity: What Each Position Is Protecting — the racial arithmetic of mandatory minimums that the drug policy debate produced: the 100:1 crack/powder disparity, the Starr/Rehavi documentation of residual federal sentencing gaps, and the four positions — racial justice advocacy, mandatory minimum abolition, community-responsive defense, and structural critique — on what the numbers show and what follows from them.
- Work and Worth: What Both Sides Are Protecting — the relationship between work and drug policy runs in both directions: the economic despair and purposelessness that follow deindustrialization are among the strongest predictors of substance use disorder, and addiction is among the strongest barriers to stable employment. The drug policy map's most contested empirical question — whether dependency is a moral failure or a response to structural conditions — is partly a question about what happens to communities when the economy's terms of exchange stop working for them.